Celgene Pays US$710 M Upfront to License Nogra Pharma’s Phase III-Ready GED-0301
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 5 (Table of Contents)
Published: 20 May-2014
DOI: 10.3833/pdr.v2014.i5.2028 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In return for a record-breaking US$710 M upfront fee, Celgene has licensed global rights to develop and commercialise Nogra Pharma’s GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA that has completed a Phase II trial in patients with active Crohn’s disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS